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To the Editor:
We have read with great inter-
est the article “Cisplatin versus 
Carboplatin-Based Regimens for the 
Treatment of Patients with Metastatic 
Lung Cancer. An Analysis of Veterans 
Health Administration Data” reported 
by Santana-Davila and colleagues in 
Journal of Thoracic oncology (May 
2014).1 We are impressed that the 
authors presented a great retrospec-
tive study with competent data and 
accurate statistical analysis. However, 
selection bias obviously existed in the 
study, as they stated in the discussion 
part. First, although the study sample 
is large enough, which included 4352 
patients, only 291 (6.7%) patients in 
the cisplatin group. Second, the inho-
mogeneity of combined chemothera-
peutic agents may affect the overall 
survival.2 Approximately 30% of 
patients treated with cisplatin were 
administered with etoposide, whereas 
only 1.7% of patients in the carbo-
platin group. Third, bevacizumab was 
used more in carboplatin group (5.9%) 
than in cisplatin group (0.7%). When 
added to paclitaxel/carboplatin, it 
can improve survival in previously 
untreated patients with advanced non-
squamous non–small-cell lung cancer 
(NSCLC).3 In addition, the authors did 
not mention the post-study treatment. 
During the last decade, many advances 
have been made in the treatment of 
advanced NSCLC, e.g., targeted ther-
apy. Further treatment after first-line 
chemotherapy may also impact on 
overall survival.
As we know, good-designed ran-
domized clinical trials provide strong 
evidence that may change the current 
treatment pattern. Rosell and colleagues 
conducted direct comparison of pacli-
taxel/carboplatin versus paclitaxel/cispl-
atin in advanced NSCLC.4 The baseline 
patient’s characteristics and follow-up 
therapy were well balanced between 
the two treatment arms. The overall 
response rate in the two arms of pacli-
taxel/carboplatin and paclitaxel/cis-
platin was 28% and 25%, respectively, 
which was similar. However, patients 
received paclitaxel/cisplatin had the sig-
nificantly longer median survival (9.8 
months) than paclitaxel/carboplatin (8.2 
months). This is confirmed by an indi-
vidual patient data meta-analysis.5 In 
patients with non-squamous histology, 
cisplatin-based chemotherapy prolonged 
survival in comparison to carboplatin-
based chemotherapy (hazard ratio = 
1.12, 95% confidence interval = 1.01–
1.23), but not in squamous histology. In 
our opinion, there are enough evidences 
to support use of cisplatin in advanced 
NSCLC, especially in non-squamous 
histology. In our daily clinical practice, 
for eligible patients with non-squamous 
NSCLC, we would like to recommend 
cisplatin preferentially.
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To the Editor:
We congratulate Shi et al1 for 
their prospective multinational, epide-
miological study of epidermal growth 
factor receptor (EGFR) mutations in 
patients from Asia with newly diag-
nosed advanced lung adenocarcinoma 
(PIONEER study) which showed that 
51.4% of tumors from 1450 patients 
had a positive EGFR mutation status. 
Although the frequency of EGFR muta-
tions was 50% or higher for patients 
of East Asian ethnicities (Vietnamese, 
64.2%; Thai, 53.8%; Chinese, 51.8%, 
and Filipino, 50.0%), it was significantly 
lower for Indian patients (21.9%). Our 
study on Malaysian patients who were 
of three major ethnicities, ie, Chinese, 
Malay, and Indian, showed that 39.5% 
of tumors from 812 patients with 
advanced adenocarcinoma were EGFR 
mutation positive.2 The frequency of 
EGFR mutations was not significantly 
different between our Chinese (40.8% 
of 517 patients), Malay (37.2% of 239 
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